Neurocrine Biosciences, Inc.
NBIX
$152.72
$1.901.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.74% | 1.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.74% | 1.12% | |||
| Cost of Revenue | 11.84% | 12.40% | |||
| Gross Profit | 21.37% | -4.76% | |||
| SG&A Expenses | 20.28% | 5.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.73% | 8.68% | |||
| Operating Income | 14.41% | -18.13% | |||
| Income Before Tax | -34.28% | 3.09% | |||
| Income Tax Expenses | -63.60% | -42.94% | |||
| Earnings from Continuing Operations | -27.03% | 28.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.03% | 28.76% | |||
| EBIT | 14.41% | -18.13% | |||
| EBITDA | 22.92% | -17.64% | |||
| EPS Basic | -27.40% | 27.99% | |||
| Normalized Basic EPS | 3.31% | -15.88% | |||
| EPS Diluted | -27.23% | 29.20% | |||
| Normalized Diluted EPS | 3.04% | -15.13% | |||
| Average Basic Shares Outstanding | 0.50% | 0.60% | |||
| Average Diluted Shares Outstanding | 0.77% | -0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||